Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 21, 2019; 25(31): 4414-4426
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4414
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4414
Disease | Symptoms |
Bile-acid malabsorption | Diarrhea, urgency |
Exocrine pancreatic insufficiency | Abdominal discomfort, bloating, diarrhea, greasy stools |
Carbohydrates intolerance | Abdominal discomfort, bloating, diarrhea |
Small intestinal bacterial overgrowth | Abdominal discomfort, bloating, constipation, diarrhea, distention, sensation of incomplete evacuation, urgency |
Small intestinal fungal overgrowth | Abdominal discomfort, bloating, diarrhea, distention, urgency |
Dyssynergic defecation | Abdominal discomfort, bloating, constipation, diarrhea, distention, sensation of incomplete evacuation, straining, urgency |
Ehlers-Danlos syndromes-hypermobility type | Abdominal pain, bloating, constipation, distention, sensation of incomplete evacuation, straining, pelvic floor dysfunction |
Mast cell activation syndrome | Abdominal discomfort, bloating, dynamic allergies, diarrhea, distention, sensation of incomplete evacuation, urgency |
Eosinophilic gastroenteritis | Abdominal pain, bloating, diarrhea |
Intra-abdominal adhesions | Abdominal pain, bloating, distention |
Irritable bowel syndrome | Abdominal discomfort, bloating, diarrhea /constipation, distention, sensation of incomplete evacuation, urgency |
Celiac disease | Abdominal discomfort, bloating, diarrhea |
Giardiasis | Abdominal discomfort, bloating, diarrhea |
Disease | Diagnosis | Treatment |
Small bowel CD | Computed tomography or magnetic resonance enterography | Drug escalation or surgery |
Bile-acid malabsorption | 75SeHCAT, 48-hour fecal bile acids, trial with bile acid binders | Bile acid sequestrants |
Exocrine pancreatic insufficiency | Fecal elastase1, trial with pancreatic enzymes | Pancreatic enzyme replacement |
Carbohydrates intolerance | Hydrogen breath test | Dietary restriction |
Small intestinal bacterial overgrowth | Lactulose or glucose breath tests: rise from baseline in H2 ≥ 20 ppm within 90 min or CH4 ≥ 10 ppm | H2: Rifaximin, doxycycline or amoxicillin CH4: Rifaximin and neomycin, or rifaximin and metronidazole, or amoxicillin-clavulanate or ciprofloxacin and metronidazole |
Small intestinal fungal overgrowth | Quantitative culture of intestinal aspirate ≥ 103 CFU/mL | Anti-fungal therapy (e.g., fluconazole) |
Dyssynergic defecation | Anorectal manometry with balloon expulsion test, defecography | Biofeedback behavior therapy |
Ehlers-Danlos syndrome-hypermobility type | Beighton score ≥ 4[105] and arthralgia, erect barium testing for visceroptosis | Pelvic physiotherapy, promotility agents |
Mast cell activation syndrome | Typical symptoms, elevated mast cell mediators (e.g., tryptase) and response to mast cell stabilizing agents | H1 blockers, H2 blockers, cromolyn sodium, referral to hematologist/allergist |
Eosinophilic gastroenteritis | Eosinophilic infiltration on pathology | Anti-inflammatory agents |
Intra-abdominal adhesions | Clinical history, previous history of adhesions | Consideration of surgical lysis of adhesions |
Giardiasis | Detection of Giardia lamblia antigens in stool | Metronidazole or nitazoxanide |
Celiac disease | IgA anti-tissue transglutaminase and serum total IgA, EGD with duodenal biopsies | Gluten-free diet |
- Citation: Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol 2019; 25(31): 4414-4426
- URL: https://www.wjgnet.com/1007-9327/full/v25/i31/4414.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i31.4414